Allelic variations in the @entity1115 gene of @entity1110 oxidase and risk of @entity8 in @entity1 with type 1 XXXX .

@entity1 @entity8 @entity3335 @entity1115 @entity6 @entity2316 @entity26 @entity1110 @entity9822 @entity1602 @entity72144 @entity454
UNASSIGNED: Oxidative stress plays a pivotal role in the pathophysiology of @entity2316 , and the @entity1110 ( @entity1110 ) oxidase system is an important source of reactive @entity26 species in @entity1602 conditions in the kidney. Plasma concentration of advanced oxidation protein products (AOPP), a marker of oxidative stress, is increased in @entity1 with @entity2316 . We investigated associations of variants in the @entity1115 gene, encoding the regulatory subunit @entity9822 (phox) of @entity1110 oxidase, with @entity2316 and plasma AOPP and @entity3335 ( @entity3335 ) concentrations in type 1 @entity6 @entity1 . Seven SNPs in the @entity1115 region were analyzed in 1357 Caucasian subjects with type 1 @entity6 from the SURGENE (n=340), GENEDIAB (n=444), and GENESIS (n=573) cohorts. Duration of follow-up was 10, 9, and 6 years, respectively. Cox proportional hazards and logistic regression analyses were used to estimate hazard ratios (HR) or odds ratios (OR) for incidence and prevalence of @entity2316 . The major G-allele of @entity72144 was associated with the incidence of renal events defined as new cases of microalbuminuria or the progression to a more severe stage of @entity8 during follow-up (HR 1.59, 95% CI 1.17-2.18, P=0.003) in SURGENE. The same allele was associated with established/advanced @entity8 (OR 1.52, 95% CI 1.22-1.92, P=0.0001) and with the incidence of @entity454 ( @entity454 ) (HR 2.01, 95% CI 1.30-3.24, P=0.001) in GENEDIAB/GENESIS pooled studies. The risk allele was also associated with higher plasma AOPP concentration in subsets of SURGENE and GENEDIAB, with higher plasma @entity3335 concentration in a subset of GENEDIAB, and with lower estimated glomerular filtration rate (eGFR) in the three cohorts. In conclusion, a functional variant in the promoter of the @entity1115 gene was associated with lower eGFR and with prevalence and incidence of @entity2316 and @entity454 in type 1 @entity6 @entity1 . These results are consistent with a role for @entity1110 oxidase in the pathophysiology of @entity8 of @entity6 .
